Fosun Pharma Issues RMB1 Billion Scientific and Technological Innovation Bonds

Reuters02-03 18:09

Fosun Pharma Issues RMB1 Billion Scientific and Technological Innovation Bonds

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the completion of the issuance of its first tranche of Scientific and Technological Innovation Bonds for 2026. The offering consists of medium-term notes with an aggregate principal amount of RMB1 billion, a term of two years, and a coupon rate of 2.4%. The bonds, named 26 Fosun Pharma MTN001 (Scientific and Technological Innovation Bond) with code 102680411, were issued at RMB100 per RMB100 in principal amount. The value date is 2 February 2026, with payment due on 2 February 2028. The leading underwriter is China Merchants Bank Co., Ltd., with joint leading underwriters including Bank of Beijing Co., Ltd., Shanghai Pudong Development Bank Co., Ltd., China Everbright Bank Company Limited, and HUA XIA BANK CO., Limited. The relevant documents are available at https://www.chinamoney.com.cn and https://www.shclearing.com.cn.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260203-12011994), on February 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608082494?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 18:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608082494","market":"nz","top_or_hot":-1,"title":"Fosun Pharma Issues RMB1 Billion Scientific and Technological Innovation Bonds","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Fosun Pharma Issues RMB1 Billion Scientific and Technological Innovation Bonds\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (Group) Co., Ltd. has announced the completion of the issuance of its first tranche of Scientific and Technological Innovation Bonds for 2026. The offering consists of medium-term notes with an aggregate principal amount of RMB1 billion, a term of two years, and a coupon rate of 2.4%. The bonds, named 26 Fosun Pharma MTN001 (Scientific and Technological Innovation Bond) with code 102680411, were issued at RMB100 per RMB100 in principal amount. The value date is 2 February 2026, with payment due on 2 February 2028. The leading underwriter is <a href=\"https://laohu8.com/S/CIHHF\">China Merchants Bank Co., Ltd.</a>, with joint leading underwriters including Bank of Beijing Co., Ltd., <a href=\"https://laohu8.com/S/600000\">Shanghai Pudong</a> Development Bank Co., Ltd., <a href=\"https://laohu8.com/S/CBVHY\">China Everbright</a> Bank Company Limited, and HUA XIA BANK CO., Limited. The relevant documents are available at https://www.chinamoney.com.cn and https://www.shclearing.com.cn.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/600196\">Shanghai Fosun</a> Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260203-12011994), on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fosun Pharma Issues RMB1 Billion Scientific and Technological Innovation Bonds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFosun Pharma Issues RMB1 Billion Scientific and Technological Innovation Bonds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-03 18:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Fosun Pharma Issues RMB1 Billion Scientific and Technological Innovation Bonds\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun</a> Pharmaceutical (Group) Co., Ltd. has announced the completion of the issuance of its first tranche of Scientific and Technological Innovation Bonds for 2026. The offering consists of medium-term notes with an aggregate principal amount of RMB1 billion, a term of two years, and a coupon rate of 2.4%. The bonds, named 26 Fosun Pharma MTN001 (Scientific and Technological Innovation Bond) with code 102680411, were issued at RMB100 per RMB100 in principal amount. The value date is 2 February 2026, with payment due on 2 February 2028. The leading underwriter is <a href=\"https://laohu8.com/S/CIHHF\">China Merchants Bank Co., Ltd.</a>, with joint leading underwriters including Bank of Beijing Co., Ltd., <a href=\"https://laohu8.com/S/600000\">Shanghai Pudong</a> Development Bank Co., Ltd., <a href=\"https://laohu8.com/S/CBVHY\">China Everbright</a> Bank Company Limited, and HUA XIA BANK CO., Limited. The relevant documents are available at https://www.chinamoney.com.cn and https://www.shclearing.com.cn.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/600196\">Shanghai Fosun</a> Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260203-12011994), on February 03, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600036","symbol_name":"招商银行","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL3z8m75:1","article_id":"2608082494","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2608082494","pubTimestamp":1770113346,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical  Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 03, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600000":"浦发银行","600015":"华夏银行","600036":"招商银行","600196":"复星医药","600398":"海澜之家","601169":"北京银行","601818":"光大银行","BK0060":"抗癌","SG9999001903.USD":"Aberdeen Standard Pacific Equity USD","00656":"复星国际","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU1048596156.SGD":"Blackrock Asian Growth Leaders A2 SGD-H","LU0011963245.USD":"abrdn SICAV I ASIA PACIFIC SUSTAINAB  LE EQUITY \"A\" (USD) ACC","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK0196":"行业龙头","BK0010":"央企","LU1934453819.USD":"AB CHINA A SHARES EQUITY PORTFOLIO \"A\" (USD) ACC","BK0278":"货币金融","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","LU0229945570.USD":"TEMPLETON BRIC \"A\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK0239":"医药制造","LU0708995153.HKD":"TEMPLETON EMERGING MARKETS \"A\" (HKD) ACC","SGXZ81163826.USD":"UNITED CHINA A-SHARES INNOVATION \"A\" (USD) ACC","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","SGXZ49509284.SGD":"United China A Shares Innovation A Acc SGD","BK0086":"举牌","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0543330566.HKD":"TEMPLETON BRIC \"A\" (HKD) ACC","LU0029874905.USD":"TEMPLETON EMERGING MARKETS \"A\" INC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","LU2213484517.USD":"FRANKLIN TEMPLETON CHINA A-SHARES \"A\" (USD) ACC","LU0047713382.USD":"BGF EMERGING MARKETS \"A2\" ACC","SG9999006597.SGD":"United China-India Dynamic Growth SGD","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","HK0000181112.HKD":"DA CHENG CHINA BALANCED \"A\" (HKD) INC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","BK0183":"MSCI概念","BK0188":"融资融券","SG9999000459.SGD":"Aberdeen Standard Pacific Equity SGD","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0253":"纺织服饰","LU1997245177.USD":"安联神洲A股基金","BK0028":"国家队","LU1808992512.USD":"AB ALL CHINA EQUITY PORTFOLIO \"A\" (USD) ACC","BK0201":"可转债","LU0231483743.USD":"abrdn SICAV I - ALL CHINA SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"复星医药发行10亿元科创债","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600000":0.9,"600015":0.9,"600036":0.9,"600196":0.9,"600398":0.9,"601169":0.9,"601818":0.9,"00656":0.9},"content_text":"Fosun Pharma Issues RMB1 Billion Scientific and Technological Innovation Bonds\n    \n\nShanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the completion of the issuance of its first tranche of Scientific and Technological Innovation Bonds for 2026. The offering consists of medium-term notes with an aggregate principal amount of RMB1 billion, a term of two years, and a coupon rate of 2.4%. The bonds, named 26 Fosun Pharma MTN001 (Scientific and Technological Innovation Bond) with code 102680411, were issued at RMB100 per RMB100 in principal amount. The value date is 2 February 2026, with payment due on 2 February 2028. The leading underwriter is China Merchants Bank Co., Ltd., with joint leading underwriters including Bank of Beijing Co., Ltd., Shanghai Pudong Development Bank Co., Ltd., China Everbright Bank Company Limited, and HUA XIA BANK CO., Limited. The relevant documents are available at https://www.chinamoney.com.cn and https://www.shclearing.com.cn.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260203-12011994), on February 03, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608082494","isCrawlerRequest":true}